# HEALER (NCT05838066)

> Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

No report yet. It can be ordered.

- Drugs tested: anbenitamab plus HB1801
- Indication: first-line HER2-positive recurrent or metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05838066
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Shanghai JMT-Bio Inc.
- Conditions: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- Interventions: Recombinant Humanized Bispecific antibody against HER2，KN026; HB1801; Pertuzumab; Trastuzumab; Docetaxel
- Enrollment: 880
- Primary outcome: Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).

## Indexed commentary on HEALER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=healer-nct05838066